Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Guillain-Barre Syndrome - Overview
Guillain-Barre Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Guillain-Barre Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Guillain-Barre Syndrome - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Annexon Inc
Cellenkos Inc
Complement Pharma BV
CuraVac Inc
Hansa Biopharma AB
Immunic Inc
Polyneuron Pharmaceuticals AG
Vitality Biopharma Inc
Guillain-Barre Syndrome - Drug Profiles
ANX-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-0801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imlifidase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMU-935 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nomacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-1018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Guillain-Barre Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Guillain-Barre Syndrome - Dormant Projects
Guillain-Barre Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 28, 2021: Immunic to participate in Scientific, Industry and Investor Conferences in July
Apr 15, 2019: Hansa Biopharma receives ethics and regulatory clearance to start Phase 2 study of imlifidase in Guillain Barr? Syndrome
Feb 16, 2018: Hansa Medical receives FDA Orphan Drug Desigtion for IdeS and the treatment of Guillain-Barre syndrome
Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome
May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Desigtion for Coversin in the European Union for Treatment of Guillain Barr? Syndrome
May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Desigtion for Coversin from the U.S. FDA for Treatment of Guillain Barr? Syndrome
Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
Jan 05, 2016: Akari Therapeutics Announces Additiol Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at Intertiol PNH Interest Group 10th Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Guillain-Barre Syndrome, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Guillain-Barre Syndrome, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Guillain-Barre Syndrome - Pipeline by Akari Therapeutics Plc, 2021
Guillain-Barre Syndrome - Pipeline by Alexion Pharmaceuticals Inc, 2021
Guillain-Barre Syndrome - Pipeline by Annexon Inc, 2021
Guillain-Barre Syndrome - Pipeline by Cellenkos Inc, 2021
Guillain-Barre Syndrome - Pipeline by Complement Pharma BV, 2021
Guillain-Barre Syndrome - Pipeline by CuraVac Inc, 2021
Guillain-Barre Syndrome - Pipeline by Hansa Biopharma AB, 2021
Guillain-Barre Syndrome - Pipeline by Immunic Inc, 2021
Guillain-Barre Syndrome - Pipeline by Polyneuron Pharmaceuticals AG, 2021
Guillain-Barre Syndrome - Pipeline by Vitality Biopharma Inc, 2021
Guillain-Barre Syndrome - Dormant Projects, 2021